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ABSTRACT Pulmonary endarterectomy (PEA) is the gold standard treatment for operable chronic
thromboembolic pulmonary hypertension (CTEPH). However, a proportion of patients with operable
disease decline surgery. There are currently no published data on this patient group. The aim of this study
was to identify outcomes and prognostic factors in a large cohort of consecutive patients with CTEPH.
Data were collected for consecutive, treatment-naive CTEPH patients at the Pulmonary Vascular
Disease Unit of the Royal Hallamshire Hospital (Sheffield, UK) between 2001 and 2014.
Of 550 CTEPH patients (mean±SD age 63±15 years, follow-up 4±3 years), 49% underwent surgery, 32%
had technically operable disease and did not undergo surgery (including patient choice n=72 and unfit for
surgery n=63), and 19% had inoperable disease due to disease distribution. The 5-year survival was
superior in patients undergoing PEA (83%) versus technically operable disease who did not undergo
surgery (53%) and inoperable due to disease distribution (59%) (p<0.001). Survival was superior in
patients following PEA compared with those offered but declining surgery (55%) (p<0.001). In patients
offered PEA, independent prognostic factors included mixed venous oxygen saturation, gas transfer and
patient decision to proceed to surgery.
Outcomes in CTEPH following PEA are excellent and superior to patients declining surgery, and
strongly favour consideration of a surgical intervention in eligible patients.
Copyright ©ERS 2018. This article is open access and distributed under the terms of the Creative Commons Attribution
Licence 4.0.
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Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially curable form of pulmonary
hypertension [1]. It may follow an acute episode of pulmonary embolism [2, 3], but can present as
unexplained pulmonary hypertension with no previous history of venous thromboembolism (VTE) [4–6].
CTEPH occurs as a consequence of failure of clot resolution and secondary pulmonary arterial
vasculopathy, leading to the development of pulmonary hypertension, right ventricular dysfunction and
ultimately death [5, 7]. Over the past 20 years the treatment of CTEPH has evolved to include pulmonary
endarterectomy (PEA) in operable cases [8] and pulmonary hypertension-specific therapy for inoperable
disease [9–14]. Balloon pulmonary angioplasty is emerging as a potential treatment option in selected
patients with inoperable disease [1, 15, 16].
PEA is currently considered the treatment of choice in patients with operable CTEPH, and is associated
with excellent symptomatic benefit and long-term survival [17–19], with 10-year survival of 72–75%
[20, 21]. Historical studies in patients treated with anticoagulation alone reported 5-year survival as low as
10% in patients with a mean pulmonary arterial pressure (mPAP) >50 mmHg [22, 23]. However,
subsequent large registries have shown significant improvements in outcome in a heterogeneous group of
nonoperated patients [24, 25]. Patients with CTEPH may be deemed inoperable where the pulmonary
vascular resistance (PVR) is considered to be out of proportion to the degree of surgically accessible
obstruction in the pulmonary vasculature [24, 26]. A significant proportion of patients who have
technically operable disease do not undergo surgery for a variety of reasons, including comorbidities and
patient choice [24–27]. To date, there are only limited data on the clinical course and rationale for
treatment decisions in this patient group. In particular, there are very limited data on patients with
technically operable disease who have declined surgery.
The aim of the current study was to provide data to help inform patient choice by identifying outcomes
and prognostic factors in a large cohort of consecutive patients with CTEPH. Some of the results have
been reported previously in abstract form [28, 29].
Methods
Consecutive, treatment-naive patients newly diagnosed with CTEPH at the Pulmonary Vascular Disease
Unit of the Royal Hallamshire Hospital (Sheffield, UK) between January 1, 2001 and November 30, 2014
were prospectively recorded in hospital databases, as part of the Sheffield ASPIRE registry (ClinicalTrials.gov
identifier NCT02565030). Baseline characteristics, treatment and follow-up data, using a census date of
November 30, 2015, were subsequently collected from hospital records and departmental databases. Baseline
characteristics, demographics, medical history, pulmonary function, exercise testing, right heart catheter
metrics, imaging and treatment were included.
The diagnosis of CTEPH was based on findings obtained after at least 3 months of anticoagulation, and
required the patient to have undergone right heart catheterisation and to have mPAP ⩾25 mmHg at rest
and at least one segmental perfusion defect detected by perfusion lung scan or pulmonary artery
obstruction seen by multidetector computed tomography angiography or conventional pulmonary
angiography with other causes of pulmonary hypertension excluded [18, 19]. Patients were further
classified into CTEPH: 1) operated group, 2) technically-operable-not-operated group and 3) patients with
nonsurgical disease distribution. The technically-operable-not-operated group was further subclassified
into four subgroups based on the reasons for the surgery not being performed: 1) declined surgery
(patient choice), 2) being unfit for surgery following multidisciplinary team (MDT) assessment,
3) CTEPH with other contributors to symptoms in addition to clot burden and 4) reason for decision not
clear. Suitability for PEA surgery was assessed by a review of clinical and radiological information by the
surgical MDT at the national PEA centre at Papworth Hospital (Cambridge, UK).
The date of diagnosis of CTEPH was recorded as the date of the first right heart catheterisation. All
patients were followed up until death or the census date of November 30, 2015. Ethical approval was
granted for this study (REC 06/Q2308/8).
Statistical analysis
Descriptive data are presented using mean and standard deviation. Comparisons between groups were made
using the t-test (for two groups) and ANOVA (with Bonferroni corrections for three groups) for continuous
This article has supplementary material available from erj.ersjournals.com
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data, and the Chi-squared test for categorical data. Survival was assessed by the Kaplan–Meier method.
Comparisons between two groups were performed using the log-rank test. Prognostic variables were assessed
using univariate and multivariate Cox regression analysis for survival. 72 variables in the CTEPH-
surgical-operated group and 71 variables in the CTEPH-surgical-not-operated and CTEPH-nonsurgical
groups were identified based on previous literature [24, 25, 30] and entered into univariate Cox regression
analysis. Variables with a p-value of <0.20 at univariate analysis and <10% missing data were included for the
multivariate analysis using the forward logistic regression method. To allow comparison between continuous
variables, hazard ratios (HRs) were scaled using the standard deviation of the variable. A p-value of <0.05
was considered statistically significant. Accuracy of variables for prediction of mortality at 3 years was
assessed using receiver operator characteristic (ROC) curve analysis. Statistical analysis was performed using
SPSS version 25 (IBM, Armonk, NY, USA) and Prism software (GraphPad, La Jolla, CA, USA).
550 patients with CTEPH (mean±SD age 63±15 years, 50% female) were identified. A flowchart giving the
classification with a detailed breakdown of patients is shown in figure 1.
Results
Patient characteristics
CTEPH (whole cohort)
Baseline characteristics for the major groups are summarised in table 1 and for technically-operable-
not-operated subgroups in supplementary table S1. There was excellent data completeness, with data on
lung function testing, exercise testing and imaging available in 94%, 94% and 93% of patients, respectively.
Right heart catheterisation was performed in all patients. Survival data to the census date were available
for all patients. The most common presenting symptoms were breathlessness (98%), ankle swelling (38%),
pre-syncope (27%) and chest pain (19%). There was no significant difference in symptoms or duration of
symptoms prior to diagnosis between patients with technically operable disease undergoing and not
undergoing surgery and those with a nonsurgical disease distribution. In terms of ethnicity, 95% of patients
were White, with no significant difference in ethnicity between the CTEPH groups. With respect to
Patients identified
with possible CTEPH 
from databases
(n=600) Patients excluded (n=50)
  CTED (n=10)
  CTEPH, unknown classification (n=5)
  Pulmonary sarcoma (n=2)
  No RHC performed (n=21)
  Others (n=12)Patients included
(n=550)
CTEPH-surgical
(n=448)
CTEPH-technically
operable-not-operated
(n=176)
Declined surgery
(patient choice)
(n=72)
Unfit for 
surgery following 
multidisciplinary 
assessment
(n=63)
CTEPH with other 
contributors to 
symptoms in addition 
to clot burden
(n=31)
Reason for decision 
not clear
(n=10)
CTEPH-nonsurgical-disease-distribution (n=102)
CTEPH-surgical-operated (n=272)
FIGURE 1 Patient cohort flowchart showing group/subgroup classification. CTEPH: chronic thromboembolic
pulmonary hypertension; CTED: chronic thromboembolic disease; RHC: right heart catheterisation.
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anticoagulation, 90% of the patients received a vitamin K antagonist, 4.5% received anti-Xa oral
anticoagulants and 5% received low-molecular-weight heparin, while 0.5% were not anticoagulated. 76% of
patients received pulmonary hypertension therapy, of whom 315 received phosphodiesterase type 5 inhibitor
(PDE-5i) monotherapy, 49 received endothelin receptor antagonist monotherapy, 22 received prostanoid
monotherapy, 18 received combination therapy with a PDE-5i and endothelin receptor antagonist, and 12
received combination therapy with a PDE-5i and prostanoid. No patients received riociguat.
CTEPH-operated group
Patients with CTEPH who underwent surgery were younger with a male predominance, and with better
exercise capacity and gas transfer compared with patients in the other groups (table 1). The mean waiting
time from date of diagnosis to surgery at the national PEA centre was 290±175 days. 74% received bridging
therapy, of whom 74% received monotherapy with PDE-5i. Bridging therapy was commenced at diagnosis
and did not lead to delay in referral for surgical consideration or time to surgery (supplementary table S2).
TABLE 1 Baseline characteristics of patients with chronic thromboembolic pulmonary hypertension (CTEPH)
CTEPH (whole
cohort)
CTEPH-operated
group
CTEPH-technically-operable-
not-operated group
CTEPH-nonsurgical-disease-
distribution group
Subjects 550 (100) 272 (49) 176 (32) 102 (19)
Age years 63±15 58±14¶,+ 69±14# 65±15#
Female 50 45+,¶ 50# 62#
BMI kg·m−2 29±7 30±7 29±8 29±6
Duration of symptoms
<1 year 15 14 17 12
1–2 years 38 40 35 33
2–5 years 24 27 19 28
>5 years 16 16 14 18
Not clear 8 3 14 9
WHO FC I/II versus III/IV 11/89 13/87+ 11/89 3/97#
ISWD m 189±177 232±185¶,+ 142±157# 155±160#
RAP mmHg 11±5 11±5 11±6 12±5
mPAP mmHg 46±11 47±11¶ 43±11#,+ 48±12¶
Cardiac index L·min−1·m−2 2.5±0.8 2.5±0.7 2.6±0.8 2.5±0.8
PCWP mmHg 12±5 12±4 12±6 11±4
PVR WU 7.7±4.3 7.7±4 7±4.6+ 8.7±4.5¶
SvO2 % 61±8 61±8 61±9 61±9
FEV1 % pred 80±35 83±43¶ 75±23# 80±24
FVC % pred 92±24 95±21 89±25 90±27
DLCO % pred 61±17 65±15¶ 55±19#,+ 61±17¶
History of acute VTE 71 74+ 74+ 57#,¶
IVC filter 3 3 5 1
Thrombophilia 5 6 3 3
History of cancer 11 6¶,+ 15# 15#
Smoking 38 38 43 30
Obesity 36 39 32 32
Splenectomy 5 3+ 3+ 12#,¶
Thyroid disorder 12 8+ 14 18#
VA shunt/PPM infection 2 2 0 4
IBD 1 1 2 2
CAD 11 10 14 7
LV dysfunction 4 2¶ 8#,+ 2¶
Valvular heart disease 2 2 2 2
CKD 7 3¶ 13# 6
COPD 19 13¶ 30# 19
PH therapy following diagnosis 76 74+ 72+ 86#,¶
Data are presented as n (%), mean±SD or %. BMI: body mass index; WHO FC: World Health Organization Functional Class; ISWD: incremental
shuttle walk distance; RAP: right atrial pressure; mPAP: mean pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PVR:
pulmonary vascular resistance; WU: Wood units; SvO2: mixed venous oxygen saturation; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; DLCO: diffusing capacity of the lung for carbon monoxide; VTE: venous thromboembolism; IVC: inferior vena cava; VA: ventriculo-atrial;
PPM: permanent pacemaker; IBD: inflammatory bowel disease; CAD: coronary artery disease; LV: left ventricular; CKD: chronic kidney
disease; COPD: chronic obstructive pulmonary disease; PH: pulmonary hypertension. #: p<0.05 compared with CTEPH-operated; ¶: p<0.05
compared with CTEPH-technically-operable-not operated; +: p<0.05 compared with CTEPH-nonsurgical-disease-distribution.
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CTEPH-technically-operable-not-operated subgroup: declined surgery (patient choice)
Compared with patients undergoing PEA, patients who declined surgery were older, more likely to be
female, and had more comorbidities and lower exercise capacity (all p<0.05) (table 2).
CTEPH-technically-operable-not-operated subgroup: not offered surgery (unfit for surgery, other
contributors to symptoms in addition to clot burden)
Patients who were unfit for surgery had worse exercise capacity, lower diffusing capacity of the lung for
carbon monoxide (DLCO), were more likely to be current smokers and had a higher prevalence of chronic
obstructive pulmonary disease (COPD) than other technically operable patients not undergoing surgery.
Patients with other contributors to symptoms in addition to clot burden (where the risk of surgery was felt
to outweigh the benefit) had milder pulmonary haemodynamics and a better exercise capacity than the
other two subgroups. The baseline characteristics of these patients are described in further detail in
supplementary table S1.
CTEPH-nonsurgical-disease-distribution group
History of VTE was less common in patients with nonsurgical disease. A history of thyroid disease and
splenectomy was also significantly more common in this subgroup compared with patients undergoing
PEA (table 1).
TABLE 2 Baseline characteristics of chronic thromboembolic pulmonary hypertension
(CTEPH)-operated group versus patients who declined surgery (patient choice)
CTEPH-operated Declined surgery (patient choice) p-value
Subjects n 272 72
Age years 58±14 68±16 <0.001
Female 45 63 0.007
BMI kg·m−2 30±7 29±7 0.485
WHO FC I/II versus II/IV 13/87 17/83 0.462
Duration of symptoms 0.009
<1 year 14 22
1–2 years 40 38
2–5 years 27 17
>5 years 16 11
Not clear 3 13
ISWD m 232±185 169±177 0.009
RAP mmHg 11±5 12±6 0.192
mPAP mmHg 47±11 46±10 0.360
Cardiac index L·min−1·m−2 2.5±0.8 2.6±0.8 0.305
PCWP mmHg 12±4 12±5 0.667
PVR WU 7.7±4 8±4 0.767
SvO2 % 61±8 61±9 0.610
FEV1 % pred 83±43 82±21 0.714
FVC % pred 95±21 96±23 0.702
DLCO % pred 65±15 61±17 0.084
History of VTE 74 69 0.489
History of cancer 6 6 0.827
Smoking 38 35 0.664
Obesity 39 26 0.048
CAD 11 8 0.620
LV dysfunction 2 6 0.131
CKD 3 14 <0.001
COPD 13 17 0.356
PH therapy following diagnosis 74 75 0.849
Data are presented as mean±SD or %, unless otherwise stated. BMI: body mass index; WHO FC: World
Health Organization Functional Class; ISWD: incremental shuttle walk distance; RAP: right atrial pressure;
mPAP: mean pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary
vascular resistance; WU: Wood units; SvO2: mixed venous oxygen saturation; FEV1: forced expiratory volume
in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; VTE: venous
thromboembolism; CAD: coronary artery disease; LV: left ventricular; CKD: chronic kidney disease; COPD:
chronic obstructive pulmonary disease; PH: pulmonary hypertension. Comparisons between continuous
variables and categorical variables were made by the t-test and the Chi-squared test, respectively.
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Outcomes
CTEPH (whole cohort)
During a mean±SD follow-up of 4±3 years, 182 (32%) patients died: 51 in the CTEPH-surgical-operated
group, 76 in the CTEPH-technically-operable-not-operated group and 49 in the CTEPH-nonsurgical-
disease-distribution group. Estimated 1-, 3- and 5-year survival from date of right heart catheterisation was
superior in the CTEPH-operated group (97%, 87% and 83%, respectively) compared with both the
CTEPH-technically-operable-not-operated group (87%, 63% and 53%, respectively) and CTEPH-
nonsurgical-disease-distribution group (92%, 75% and 59%, respectively) (p<0.001) (figure 2).
CTEPH-operated group
Persistent pulmonary hypertension (defined by mPAP ⩾25 mmHg) post-PEA surgery was found in 108
(40%) patients in our study. There was no significant difference in long-term survival between the patients
who developed pulmonary hypertension post-PEA versus the patients who did not develop pulmonary
hypertension post-PEA (p=0.288). However, those with a post-operative PVR above the median (3 Wood
units (WU)) had a worse prognosis following surgery (p=0.013). There was no significant difference in
survival between patients who received bridging therapy versus patients who did not receive bridging
therapy prior to surgery (3-year survival 86% versus 90%; p=0.447), although those who received bridging
therapy had more severe pulmonary haemodynamics at diagnosis (mPAP 50 versus 40 mmHg and PVR
8.8 versus 5 WU; both p<0.001).
CTEPH-technically-operable-not-operated subgroup: declined surgery (patient choice)
The estimated 5-year survival of patients declining surgery was significantly worse than those undergoing
PEA (55% versus 83%; p<0.001) (figure 3a). The impact of age on long-term outcome in patients offered
surgery is shown in figure 3b–d. A survival benefit was seen in patients aged <60 years (p=0.036) and
⩾60 years (p<0.001) (figure 3b and c, respectively). A trend in favour of surgery was observed in more
elderly patients aged ⩾70 years (p=0.056) (figure 3d).
CTEPH-technically-operable-not-operated subgroup: not offered surgery (unfit for surgery, other
contributors to symptoms in addition to clot burden)
Patients deemed unfit for surgery had a significantly worse survival than patients offered surgery who
declined, who had a significantly worse survival than patients with other contributors to symptoms in
addition to clot burden (p<0.05) (supplementary figure S1).
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FIGURE 2 Kaplan–Meier estimates of survival from date of diagnosis in the chronic thromboembolic pulmonary
hypertension (CTEPH)-operated, CTEPH-technically-operable-not-operated and CTEPH-nonsurgical patient groups.
https://doi.org/10.1183/13993003.00589-2018 6
PULMONARY VASCULAR DISEASES | S.R. QUADERY ET AL.
Prognostic indicators
CTEPH (whole cohort)
Univariate analysis of the whole cohort identified a number of predictors of outcome (table 3).
Independent predictors of mortality identified from multivariate analysis were: PEA (HR 0.38, 95% CI
0.23–0.63), DLCO (HR 0.59, 95% CI 0.46–0.74), mixed venous oxygen saturation (SvO2) (HR 0.71, 95% CI
0.57–0.87), history of cancer (HR 2.24, 95% CI 1.28–3.95), chronic kidney disease (HR 2.20, 95% CI 1.22–
4.71) and age (HR 1.39, 95% CI 1.06–1.80).
CTEPH-offered-surgery
Four independent predictors of survival were identified in the combined group of patients offered surgery:
patient choice (HR 3.64, 95% CI 1.95–6.81), SvO2 (HR 0.66, 95% CI 0.49–0.89), DLCO (HR 0.67, 95% CI
0.47–0.95) and the presence of coronary artery disease (HR 2.34, 95% CI 1.11–4.96) (table 4).
CTEPH-technically-operable-not-operated subgroup: declined surgery (patient choice)
ROC curve analysis for prediction of 3-year mortality was performed for the three continuous prognostic
variables identified at univariate analysis (supplementary table S3): DLCO (area under the curve (AUC)
0.87), RAP (AUC 0.81) and SvO2 (AUC 0.85). Using median thresholds of DLCO 62%, RAP 11 mmHg and
SvO2 62%, the sensitivity, specificity, positive predictive value and negative predictive value for predicting
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FIGURE 3 Kaplan–Meier estimates of survival from date of diagnosis comparing outcomes in patients with technically operable chronic
thromboembolic pulmonary hypertension (CTEPH) who were offered surgery and underwent pulmonary endarterectomy versus patients who
declined surgery (patient choice): a) all patients, b) patients <60 years, c) patients ⩾60 years and d) patients ⩾70 years.
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3-year mortality were 100%, 63%, 31% and 100%, 80%, 70%, 32% and 95%, and 90%, 60%, 30% and 97%,
respectively.
CTEPH-technically-operable-not-operated group
For the whole group, univariate analysis identified a number of predictors of outcome, including age,
World Health Organization Functional Class, exercise capacity, pulmonary haemodynamics and
comorbidities. Univariate and multivariate analysis for each of the three subgroups is shown in
supplementary table S3. Independent predictors of outcome were SvO2 (HR 0.53, 95% CI 0.38–0.76), DLCO
(HR 0.54, 95% CI 0.38–0.75) and cancer (HR 4.10, 95% CI 2.02–8.37). In those who declined surgery, SvO2
(HR 0.24, 95% CI 0.12–0.51) was an independent predictor of survival; in those unfit for surgery, exercise
capacity (HR 0.51, 95% CI 0.26–0.96), PVR (HR 1.56, 95% CI 1.02–2.38) and comorbidities (cancer (HR
11.46, 95% CI 3.46–37.99) and chronic kidney disease (HR 8.87, 95% CI 2.45–32.17)) independently
predicted outcome, while in patients with other contributors to symptoms in addition to clot burden,
cancer (HR 9.93, 95% CI 1.98–49.85) was an independent predictor of outcome.
Discussion
To the best of our knowledge, this is the first study primarily focusing on patients with technically
operable CTEPH who did not undergo PEA. Patient choice, lack of fitness for surgery and the presence of
other contributors to symptoms in addition to clot burden were the commonest reasons for patients not
undergoing surgery, while pulmonary haemodynamic severity, DLCO and comorbidities were independent
predictors of survival. In addition, in a large cohort of consecutive patients with CTEPH we have shown
that long-term survival of patients undergoing PEA is excellent and superior to patients declining surgery,
strongly favouring consideration of a surgical intervention in eligible patients.
CTEPH (whole cohort)
PEA is considered the treatment of choice for suitable patients with CTEPH, and is thought to provide the
best prospect of improved quality and quantity of life [17–19]. Our study, conducted in a large cohort of
consecutive patients with CTEPH, confirms the results of the international CTEPH Registry that PEA is
an independent predictor of survival [24]. In operated patients it was associated with an excellent
long-term outcome with an estimated 5-year survival of 83%, similar to data from the international [24],
TABLE 3 Cox regression survival analysis for chronic thromboembolic pulmonary hypertension (CTEPH) (whole cohort)
Covariate Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age# per 15 years 1.68 (1.40–2.02) <0.001 1.39 (1.06–1.80) 0.016
BMI# per 7 kg·m−2 0.82 (0.68–0.99) 0.046
WHO FC I/II or III/IV; Ref.=I/II 2.20 (1.12–4.30) 0.021
ISWD# per 177 m 0.51 (0.41–0.63) <0.001
RAP# per 5 mmHg 1.30 (1.14–1.49) <0.001
Cardiac index# per 0.8 L·min−1·m−2 0.75 (0.64–0.88) <0.001
PVR# per 4.3 WU 1.36 (1.16–1.60) <0.001
SvO2# per 8% 0.66 (0.57–0.76) <0.001 0.71 (0.57–0.87) 0.001
FEV1# per 35% 0.65 (0.49–0.86) 0.002
DLCO# per 17% 0.52 (0.44–0.62) <0.001 0.59 (0.46–0.74) <0.001
VTE Ref.=absent 0.70 (0.51–0.95) 0.020
Cancer Ref.=absent 2.33 (1.58–3.45) <0.001 2.24 (1.28–3.95) 0.005
Obesity Ref.=absent 0.68 (0.49–0.95) 0.023
Thyroid disorders Ref.=absent 1.35 (0.88–2.06) 0.166
CAD Ref.=absent 2.17 (1.47–3.18) <0.001
LV dysfunction Ref.=absent 1.77 (0.86–3.48) 0.096
CKD Ref.=absent 2.33 (1.44–3.77) 0.001 2.20 (1.22–4.71) 0.021
PEA Ref.=not performed 0.31 (0.22–0.43) <0.001 0.38 (0.23–0.63) <0.001
Data shown for univariate analysis where p<0.20; 72 variables were imported into univariate analysis. HR: hazard ratio; Ref.: reference
parameter; BMI: body mass index; WHO FC: World Health Organization Functional Class; ISWD: incremental shuttle walk distance; RAP: right
atrial pressure; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; WU: Wood units; SvO2: mixed venous oxygen
saturation; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; VTE: venous thromboembolism;
CAD: coronary artery disease; LV: left ventricular; CKD: chronic kidney disease; PEA: pulmonary endarterectomy. #: these variables are scaled
so that the hazard ratio is the change by 1 SD.
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Austrian [31, 32], Spanish [25], Italian [33] and Dutch CTEPH registries [34]. Although 482 patients
(82%) had technically operable disease distribution, despite the proven benefits of PEA only 272 (49% of
the total cohort) underwent surgery. Previous registries reported similar proportions of patients who
underwent PEA, but provided only limited data on reasons for not undergoing surgery and predictors of
long-term outcome [24, 34, 35].
CTEPH-technically-operable-not-operated group
176 (39% of patients with technically operable disease) did not undergo surgery due to patient choice
(n=72), concerns regarding fitness to undergo surgery (n=63) or having other contributors to symptoms in
addition to clot burden (n=31 where the benefits of surgery were felt to be minimal). The 5-year survival
in patients with technically accessible disease not undergoing surgery was 53%, significantly better than
historical studies of patients with CTEPH treated with anticoagulation alone [22, 23]. Survival was related
to the rationale underpinning the treatment decision, with those declining surgery having a superior
survival to those who were deemed unfit for surgery. Not only did markers of disease severity such as SvO2
and DLCO independently predict survival, but also the presence of comorbidities, emphasising the impact
of conditions apart from the pulmonary vasculature when making treatment decisions.
CTEPH-technically-operable-not-operated subgroup: declined surgery (patient choice)
The proportion of patients with technically operable disease who were offered surgery (n=344) but
declined (n=72 (21%)) is larger than previously noted in other registries and may reflect the consecutively
enrolled nature of our study [24, 34, 35]. These data highlight the importance of patients being referred
for assessment and counselling by a PEA surgeon and experienced MDT. In patients who declined surgery
the severity of pulmonary haemodynamics and DLCO predicted outcome, with median thresholds for
DLCO, right atrial pressure and SvO2 having negative predictive values for 3-year mortality >95%. For a
selected cohort of patients who despite counselling decline surgery this information may be useful,
although it must also be emphasised that quality of life benefits in the majority of patients are greater
with surgery [36, 37]. In contrast, patients with severe haemodynamics assessed to be good surgical
candidates may find data highlighting a poor prognosis in the absence of a surgical intervention an aid to
decision making.
This study has demonstrated a significantly superior survival in patients with CTEPH who were offered
surgery and underwent PEA compared with those who declined. Although patients declining surgery were
older, with a poorer exercise capacity and more comorbidities, declining surgery due to patient choice was
TABLE 4 Cox regression survival analysis in chronic thromboembolic pulmonary hypertension (CTEPH)-technically-operable
who were offered surgery (operated group and declined surgery (patient choice) subgroups)
Covariate Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age# per 15 years 1.71 (1.30–2.25) <0.001
WHO FC I/II or II/IV; Ref.=I/II 3.98 (1.25–12.65) 0.019
Cardiac arrhythmia Ref.=absent 2.16 (1.03–4.53) 0.043
ISWD# per 185 m 0.56 (0.41–0.75) <0.001
RAP# per 6 mmHg 1.57 (1.25–1.98) <0.001
PVR# per 4 WU 1.39 (1.08–1.78) 0.009
SvO2# per 8% 0.62 (0.49–0.77) <0.001 0.66 (0.49–0.89) 0.006
DLCO# per 16% 0.56 (0.42–0.75) <0.001 0.67 (0.47–0.95) 0.025
VTE Ref.=absent 0.62 (0.39–0.98) 0.045
Cancer Ref.=absent 1.77 (0.85–3.69) 0.127
Obesity Ref.=absent 0.55 (0.33–10.92) 0.024
Thyroid disorders Ref.=absent 1.65 (0.87–3.15) 0.122
CAD Ref.=absent 2.21 (1.24–3.94) 0.007 2.34 (1.11–4.96) 0.026
CKD Ref.=absent 1.90 (0.82–4.38) 0.132
Patient choice Ref.=surgery 2.56 (1.57–4.16) <0.001 3.64 (1.95–6.81) <0.001
Data shown for univariate analysis where p<0.20; 72 variables were imported into univariate analysis. HR: hazard ratio; Ref.: reference
parameter; WHO FC: World Health Organization Functional Class; ISWD: incremental shuttle walk distance; RAP: right atrial pressure; PVR:
pulmonary vascular resistance; WU: Wood units; SvO2: mixed venous oxygen saturation; DLCO: diffusing capacity of the lung for carbon
monoxide; VTE: venous thromboembolism; CAD: coronary artery disease; CKD: chronic kidney disease. #: these variables are scaled so that the
hazard ratio is the change by 1 SD.
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an independent predictor of a worse outcome. In patients who declined compared with those who
underwent surgery, there was a female predominance [27] and sex-specific factors related to risk-taking
may play a role [38]. Given the findings of this study and the benefit of PEA, more work is required to
understand the factors underlying decisions to decline surgery.
Unfit for surgery
In expert hands PEA has a perioperative mortality of <5% and offers the best chance of longer-term
survival, but requires careful assessment of risks versus benefits for individual patients [21, 24]. We found
63 patients (14% of those with technically operable disease) were deemed unfit for surgery by the MDT.
These patients had a significantly poorer survival than those declining surgery. Alternative interventions to
surgery such as balloon pulmonary angioplasty may appear attractive in these patients, but the presence of
significant comorbidities may be primary determinants of survival. A meticulous assessment balancing the
potential symptomatic benefit versus the risks of such interventions is therefore paramount where
mortality benefit is not clear.
CTEPH-nonsurgical-disease-distribution group
19% of all patients were deemed to have nonsurgical disease distribution. This proportion is similar to the
international CTEPH Registry (20%) [24], but less than the UK (32%) [35] and Dutch (26%) [34]
registries. This may reflect an increasing willingness among surgeons to operate on patients with disease
that would previously have been considered too distal to benefit from surgery. Indeed, a number of centres
have shown that outcomes in patients with type 3 disease (more distal) in expert hands are now similar to
more proximal disease (type 1 and 2) [21, 39]. We noted a female predominance, an increased incidence
of thyroid disease and splenectomy, and reduced incidence of VTE in this group (table 1), in keeping with
previous reports [33].
CTEPH-operated group: timing of surgery and pulmonary vasodilator therapy
The mean±SD time from diagnosis to PEA surgery was 290±175 days, longer than in previously reported
studies [24, 32, 35, 40], but in line with waiting times for surgery in the UK during the duration of this
study, although UK waiting times are now falling. In keeping with data from the international CTEPH
Registry, the duration of delay did not impact on long-term survival [24]. A large number of patients were
bridged to PEA with off-label pulmonary arterial hypertension-specific therapies (74%). Although there is
no published evidence to support this practice, this may reflect the longer time from referral to surgery in
the UK during the study period compared with that reported in the international CTEPH Registry [24].
Importantly, bridging therapy had no effect on time to referral or to surgery. Patients receiving bridging
therapy in the present study had similar haemodynamics to those who received bridging therapy in the
international CTEPH Registry, while patients who were not bridged to surgery had milder haemodynamics
than those in the international CTEPH Registry [24]. Importantly, in our study receiving bridging therapy
was not associated with adverse outcome at univariate analysis.
Limitations
This study pre-dates the availability of balloon angioplasty and riociguat therapy in the UK, and therefore
the impact of these interventions and their potential benefits cannot be assessed. Although patient-specific
data were enriched by retrospective case note review and interrogation of databases, this resulted in higher
levels of data completeness than in other contemporary registries. Furthermore, the consecutive nature of
enrolment in the ASPIRE registry reduces recruitment bias associated with previous nonconsecutively
enrolled studies. This study provides no data on the reasons for patients declining surgery. Although the
results suggest that surgery improves survival in patients with technically operable disease who were
offered surgery, patients judged to be unfit for surgery by the MDT and those in whom there were other
contributors to symptoms in addition to clot burden were excluded. For the individual patient, factors
including age and comorbidities will influence outcome following surgery. How these factors influence the
patient’s decision requires further research.
Conclusions
We report results from a large consecutively enrolled registry of patients with CTEPH, and have been able
to compare characteristics and have identified predictors of survival in patients who did not undergo
surgery despite having technically operable disease. Our data show that survival of patients undergoing
PEA is excellent and superior to patients declining surgery, and strongly favours consideration of a
surgical intervention in eligible patients. More work is required to understand factors influencing decision
making in CTEPH, and to ensure that patients are counselled and supported to make informed decisions.
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